PTNS for Female Patients Suffering From Multiple Sclerosis
Stopped early · Not applicable · Has a placebo group
Conditions studied: Multiple Sclerosis, Overactive Bladder
In brief
This is a pilot, single blind, randomized, sham-controlled trial to assess the benefit of Percutaneous Tibial Nerve Stimulation (PTNS) in treating bladder overactivity (OAB) symptoms in multiple sclerosis (MS) patients. The data generated by this study would provide support for a future multi-institutional, randomized prospective trial.
Key facts
- Study ID
- NCT05422625
- Run by
- Corewell Health East
- People needed
- 2
- Starts
- 2023-01-09
- Expected to finish
- 2023-08-03
- Last updated by the study team
- 2024-10-09
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- Women with diagnosis for Multiple Sclerosis (Clinically isolated syndrome (CIS), relapsing remitting (RRMS), secondary progressive (SPMS), and/or primary progressive (PPMS)), 18 years of age or older
- Self-reported bladder symptoms > 3 months
- Discontinued antimuscarinics/beta-3 agonists for > 2 weeks, and remain off for the duration of the study
- Capable of giving informed consent
- Ambulatory and able to use toilet independently without difficulty
- Capable and willing to follow all study-related procedures
- If of childbearing age, agree to practice approved birth-control methods (oral contraceptives, condom barrier, injection, diaphragm or cervical cap, vaginal contraceptive ring, intrauterine device (IUD), implantable contraceptive, surgical sterilization (bilateral tubal ligation), vasectomized partner(s))
- Subject agrees not to start any new treatments for urinary symptoms (medication or otherwise) during the treatment and follow-up periods.
- Subject agrees to maintain a stable dose on all current medications throughout the treatment and follow-up period.
You may not qualify if…
- Pregnant or planning to become pregnant during study duration
- Botox (BTX) use in bladder or pelvic floor muscles within past 6 months
- Pacemakers or implantable defibrillators
- Current urinary tract infection
- Active use of neuromodulation in any other form. If patient has InterStim, must be turned off for 2 weeks for a washout period and remain off during the entirety of the study.
- Current use of Transcutaneous Electrical Nerve Stimulation (TENS) in pelvic region, back or legs
- Previous PTNS treatment
- Participation in any clinical investigation involving or impacting gynecologic, urinary, or renal function within past 4 weeks
- Note: For the sake of preserving scientific integrity, one or more of the eligibility criteria have been left off the list posted while the trial is ongoing. A full list of eligibility criteria will be posted upon completion of the trial.
Where it is running
- Beaumont Hospital - Royal Oak — Royal Oak, Michigan, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.